Eric Furfine PhD

Dr. Furfine joined Ohana Biosciences as Chief Scientific Officer. Previously, Dr. Furfine was at Eleven Biotherapeutics, where his roles included Chief Scientific Officer and President of Research and Development, and where he led the discovery and early development of EBI-031, an IL-6 inhibitory antibody for the treatment of posterior ocular inflammatory diseases. Dr. Furfine currently serves on the scientific advisory boards of Mosaic Biosciences and OH2 Laboratories.

Prior to Eleven Biotherapeutics, Dr. Furfine served as the Senior Vice President of Research and Preclinical Development of Adnexus Therapeutics, Inc., a Bristol-Myers Squibb research and development company, where his group discovered Adnectins, which advanced into clinical development. Prior to that, he was Vice President of Preclinical Development at Regeneron, where he led the non-clinical development and clinical pharmacology of ARCALYST, EYLEA, and ZALTRAP. Dr. Furfine began his career in the pharmaceutical industry at Burroughs Welcome, which became GlaxoSmithKline, where he was the inventor of LEXIVA.

Dr. Furfine received an A.B. in Chemistry from Washington University in St. Louis, a Ph.D. from Brandeis University in Biochemistry, and did postdoctoral research in molecular parasitology at the University of California, San Francisco, CA.